Research priorities to move ctDNA assays into clinical decision making in early-stage breast cancer
Circulating tumor DNA (ctDNA)-based Minimal Residual Disease (MRD) assays are increasingly utilised in early-stage breast cancer; but evidence for decision-making remains incomplete. The Breast International Group (BIG) and National Clinical Trials Network (NCTN) ctDNA working group identified research priorities to advance these assays toward clinical utility: clinical trial designs proving utility and affordability; validating ctDNA dynamics as surrogate endpoint; standardising assays; and evaluating patient-reported outcomes and equity. Prospective, randomised evidence remains essential before implementation.
Authors
- Yara George Abdou (ORCID: https://orcid.org/0000-0002-4827-8613)
- Séamus O’Reilly (ORCID: https://orcid.org/0000-0002-2887-7336)
- gabriele zoppoli
- Catherine Alix‐Panabières (ORCID: https://orcid.org/0000-0002-6401-2903)
- Stefania Morganti (ORCID: https://orcid.org/0000-0001-5284-9944)
- David W. Cescon (ORCID: https://orcid.org/0000-0002-1080-0998)
- Michail Ignatiadis (ORCID: https://orcid.org/0000-0002-4493-3748)
- Mariya Rozenblit (ORCID: https://orcid.org/0000-0003-0244-429X)
- Eric Winer
- Angela De Michele
- Shelley Hwang
- Nancy Lin
- Heather Parsons
- Antonio Wolff
- Maria Coakley
- Philippe Bedard
- David Cameron
Institutions
- University of North Carolina at Chapel Hill (US)
Publication Details
- Journal
- UNC Libraries
- Published
- 2026-10-29
- DOI
- https://doi.org/10.17615/gwtq-k006
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00